At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Right Ventricular Function After Withdrawal of Phosphodiesterase-5 Inhibitors in Left Ventricular Assist Device Recipients
In Brief
A clinical study evaluating withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients for Phosphodiesterase Inhibitor Adverse Reaction and Right-Sided Heart Failure. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Refractory right heart failure is common during the postoperative period after left ventricular assist device implantation. Oral phosphodiesterase-5 inhibitors are oft initiated in order to facilitate weaning from the intravenous inotropic substances. following this period many patients continue to receive the same medication in the long term, despite missing data on its therapeutic effect on right ventricular function.We hypothesise that beyond the acute postoperative period no additional benefit from the phosphodiesterase-5 inhibitors exists. The aim of the study is a detailed clinical and echocardiographic assessment of the right ventricular function after discontinuation of the medication in patients pretreated for at least one month after receiving left ventricular assist device.
Study Details
Timeline
Interventions
discontinuation of the oral medication with a phosphodiesterase-5 inhibitor